203. 22q11.2欠失症候群 22q11.2 deletion syndrome Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05149898 (ClinicalTrials.gov) | March 3, 2020 | 5/10/2021 | Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | 22Q Deletion Syndrome | Drug: ZYN002 | Zynerba Pharmaceuticals, Inc. | NULL | Recruiting | 4 Years | 17 Years | All | 20 | Phase 1/Phase 2 | United States;Australia |